Taking Immunotherapy To Greater Heights Our Immunotherapy Is Positioned To Improve The Lives Of Transplant Patients And People Living With Immuneand Hematological Diseaseswe Envision A Future Where More Transplant Patients Are Able To Achieve Lasting Organ Tolerancemedeor Is Now In Phase 3 Of A Pioneering Transplant Programwith No Reported Organ Loss Due To Acute Rejection 20 Years Of Researchone Powerful Platform Our Company Was Founded With A Life Changing Mission In Mindto Enable The Immune System In One Human To Benefit Anotherour Goals Include A World In Which Organ Transplant Patients Are Able To Minimize Or Eliminate The Need For Immunosuppressant Drugs And Their Associated Toxicitieswhile Living Full And Healthy Livesfurthermorewe Intend To Address Unmet Needs Across Numerous Hematologic And Rare Diseases Where Chimerism Would Provide Significant Clinical Benefit What Began More Than 20 Years Ago At Stanford University Has Evolved Into A Promising Biomedical Platform That Has Helped To Enable Pivotal Immunotherapy Clinical Trials With Exciting Results
